\n<\/p>\n
FDA Law-Not Hemp, Marijuana Politics-Will Decide the Future of Cannabinoid Medicine.<\/strong><\/i><\/p>\n Why “Full-Spectrum CBD” Narratives Are Collapsing-and Why MMJ International Holdings DRUG Development Strategy Was Right All Along” stated Duane Boise, CEO MMJ International Holdings.<\/strong><\/i><\/p>\n<\/p><\/div>\n For nearly a decade, headlines, op-eds, and trade press promoted the idea that hemp-derived or “full-spectrum” CBD products could evolve into federally recognized medicine without complying with the Food, Drug, and Cosmetic Act. That theory has now collapsed-legally, scientifically, and legislatively.<\/strong><\/a><\/p>\n What remains standing is the pathway that MMJ International Holdings<\/strong> chose in 2018: FDA-regulated botanical drug development under full DEA and FDA oversight<\/strong>.<\/p>\n The Era of Fake News Is Over-The Era of Statute Has Begun<\/strong><\/a><\/p>\n Recent federal legislation and appropriations language have fundamentally altered the cannabinoid landscape:<\/p>\n Hemp is now defined by total THC<\/strong>, not delta-9 alone<\/p>\n<\/li>\n Synthetic and semi-synthetic cannabinoids are banned<\/p>\n<\/li>\n Commercially viable “full-spectrum CBD” products are effectively eliminated<\/p>\n<\/li>\n A 12-month implementation clock is already running<\/p>\n<\/li>\n<\/ul>\n No executive order, press release, or lobbying campaign can override enacted law. The consumer CBD category-marketed for years as “wellness”-is being legislated out of existence.<\/p>\n This is not politics. It is statutory enforcement.<\/strong><\/p>\n Why the “Full-Spectrum CBD” Argument Was Always Legally Wrong<\/strong><\/p>\n Under FDA law:<\/p>\n There is no pathway<\/strong> for consumer CBD-hemp-derived or otherwise-to Medicare eligibility, insurance reimbursement, or federal medical recognition without completing the same botanical drug process required of every other medicine<\/strong>.<\/p>\n That process is long by design.<\/strong><\/p>\n And MMJ completed it.<\/strong><\/p>\n MMJ’s Seven-Year Record: Process, Not Promotion<\/strong><\/p>\n MMJ did not chase loopholes. It followed federal law.<\/p>\n Over seven years, MMJ completed what most of the industry avoided:<\/p>\n FDA Orphan Drug Designation<\/strong> (Huntington’s Disease)<\/p>\n<\/li>\n FDA IND-authorized clinical programs<\/strong> (Huntington’s & Multiple Sclerosis)<\/p>\n<\/li>\n Defined botanical raw material and controlled chemovar<\/p>\n<\/li>\n Reproducible extraction and formulation<\/p>\n<\/li>\n Stability testing under ICH conditions<\/p>\n<\/li>\n Pharmaceutical GMP manufacturing<\/p>\n<\/li>\n Finished soft-gel capsule dosage forms<\/strong><\/p>\n<\/li>\n DEA Schedule I research compliance<\/p>\n<\/li>\n<\/ul>\n MMJ now has two fully developed drug candidates-MMJ-001 and MMJ-002-ready for FDA clinical advancement.<\/strong><\/p>\n This is not theoretical science.<\/strong> The Central Contradiction: FDA Success, DEA Paralysis<\/strong><\/p>\n Despite meeting FDA standards, MMJ remains stalled by one unresolved step: DEA issuance of a bulk manufacturing registration<\/strong>.<\/p>\n That delay is no longer defensible.<\/p>\n The Department of Justice has formally conceded that the DEA’s Administrative Law Judge system-used to stall MMJ’s application-was unconstitutional<\/strong>. No lawful evidentiary hearing ever occurred. No valid final decision exists.<\/p>\n Meanwhile, federal courts are openly questioning years-long DEA inaction in parallel Schedule I cases, signaling that patience with administrative delay is wearing thin.<\/p>\n For patients with Huntington’s Disease and Multiple Sclerosis, this is not a paperwork issue-it is the denial of timely access to potential therapies that have already cleared scientific scrutiny.<\/p>\n Two Futures Remain-Only One Is Medicine<\/strong><\/p>\n The United States now has only two lawful cannabinoid futures<\/strong>:<\/p>\n FDA-Approved Botanical Drugs<\/strong><\/p>\n Prescription only<\/p>\n<\/li>\n Insurance eligible<\/p>\n<\/li>\n Federally lawful<\/p>\n<\/li>\n Scalable globally<\/p>\n<\/li>\n<\/ul>\n This is MMJ’s lane.<\/strong><\/p>\n State-Legal Cannabis Markets<\/strong><\/p>\n The former “third lane”-over-the-counter hemp CBD-does not survive under current law.<\/strong><\/p>\n Why the Fake News Persists-and Why It Will End<\/strong><\/p>\n Misinformation thrives in regulatory gray zones. When hemp products disappear from shelves, when banks refuse accounts, when insurers deny coverage, and when FDA approvals-not headlines-define medicine, the narratives will stop.<\/p>\n MMJ did the hard work while others wrote op-eds.<\/p>\n Congress has now confirmed: the shortcut era is over<\/strong>.<\/p>\n The Final Word<\/strong><\/p>\n This is not about ideology, access rhetoric, or market nostalgia. You cannot:<\/strong><\/p>\n Backdoor cannabis through hemp<\/strong><\/p>\n<\/li>\n Bypass FDA science<\/strong><\/p>\n<\/li>\n Claim medicine without trials<\/strong><\/p>\n<\/li>\n Ignore botanical drug standards<\/strong><\/p>\n<\/li>\n<\/ul>\n MMJ followed the law when it was unpopular to do so. BUCKLE UP!!<\/p>\n MMJ is represented by attorney Megan Sheehan<\/strong><\/a>.<\/p>\n CONTACT:<\/strong>
\n WASHINGTON, DC, December 30, 2025 (Newswire.com)
\n –
\n <\/strong>While Congress has dismantled the intoxicating hemp market and federal agencies move to realign cannabis policy with medical science, a long-standing truth is finally unavoidable: there are no shortcuts to cannabinoid medicine development under U.S. law<\/strong><\/a>.<\/a><\/p>\n\n
\n
This is finished pharmaceutical work.<\/strong><\/p>\n\n
Those zones are closing.<\/p>\n
It is about federal drug law.<\/p>\n\n
That path is now the only<\/strong> path left.<\/p>\n
Madison Hisey
MHisey@mmjih.com<\/a>
203-231-8583<\/p>\n